Caspofungin-Induced Cardiotoxicity in Patients Treating for CandidemiaRoya Sattarzadeh Badkoubeh, Mostafa Farajpour & 5 morePDF429 KB
Risk Factors and Clinical Analysis of Candidemia in Very-low-birth-weight NeonatesJinjian FuPDF219 KB
Population Pharmacokinetic Modeling and Target Attainment Analyses of Rezafungin for the Treatment of Candidemia and Invasive CandidiasisStefan Roepcke & Julie Passarell & Helen Walker & Shawn Flanagan2023PDF2.6 MB
Outcomes by Candida Spp. in the ReSTORE Phase 3 Trial of Rezafungin Versus Caspofungin for Candidemia And/or Invasive CandidiasisJeffrey B. Locke & Chris M. Pillar & Mariana Castanheira & Cecilia G. Carvalhaes & David Andes & Jalal A. Aram & Christina Andrzejewski & Ken Bartizal & Anita F. Das & Taylor Sandison & George R. Thompson III & Peter G. Pappas2024PDF370 KB
Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida aurisJose A. Vazquez & Peter G. Pappas & Kenneth Boffard & Fathima Paruk & Paul A. Bien & Margaret Tawadrous & Eric Ople & Pamela Wedel & Iwona Oborska & Michael R. Hodges2023PDF530 KB